| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone) is a naturally occurring naphthoquinone derivative. –Plumbagin can undergo redox cycling to generate reactive oxygen species (ROS) -apototosis, activation of caspases, modulation of Bax, Bcl‑2, loss of MMP. -Cell cycle arrest in cancer cells, often at the G0/G1, or G2/M phases. -May inhibit NF‑κB activation – MAPK Pathways – PI3K/Akt Pathway -Downregulation of (VEGF) and matrix metalloproteinases (MMPs). -Seems capable of raising ROS in normal and cancer cells (#2004) -ic50 cancer cells 1-10uM, normal cells >10uM
|
| Source: |
| Type: |
| JNK acts synergistically with NF-κB, JAK/STAT, and other signaling molecules to exert a survival function. Janus signaling promotes cancer cell survival. JNK, or c-Jun N-terminal kinase, is a member of the mitogen-activated protein kinase (MAPK) family. It plays a crucial role in various cellular processes, including cell proliferation, differentiation, and apoptosis (programmed cell death). JNK is activated in response to various stress signals, such as UV radiation, oxidative stress, and inflammatory cytokines. JNK activation can promote apoptosis in cancer cells, acting as a tumor suppressor. However, in other contexts, it can promote cell survival and proliferation, contributing to tumor progression. JNK is often unregulated in cancers, leading to increased cancer cell proliferation, survival, and resistance to apoptosis. This activation is typically associated with poor prognosis and aggressive tumor behavior. |
| 2005- | PLB, | Plumbagin induces apoptosis in lymphoma cells via oxidative stress mediated glutathionylation and inhibition of mitogen-activated protein kinase phosphatases (MKP1/2) |
| - | in-vivo, | Nor, | EL4 | - | in-vitro, | AML, | Jurkat |
| 5162- | PLB, | Plumbagin induces cell cycle arrest and apoptosis through reactive oxygen species/c-Jun N-terminal kinase pathways in human melanoma A375.S2 cells |
| - | vitro+vivo, | Melanoma, | A172 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:299 Target#:168 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid